Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Chul S. Ha; Michael LeBlanc; Heiko Schöder; Chelsea C. Pinnix; Nancy L. Bartlett; Andrew M. Evens; Eric D. Hsi; Lisa Rimsza; Michael V. Knopp; Jun Zhang; John P. Leonard; Brad S. Kahl; Hongli Li; Sonali Smith; Louis S. Constine; Jonathan W. Friedberg

doi:10.1080/10428194.2020.1768388

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Chul S. Ha, Michael LeBlanc, Heiko Schöder, Chelsea C. Pinnix, Nancy L. Bartlett, Andrew M. Evens, Eric D. Hsi, Lisa Rimsza, Michael V. Knopp, Jun Zhang, John P. Leonard, Brad S. Kahl, Hongli Li, Sonali Smith, Louis S. Constine, Jonathan W. Friedberg

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2–58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates. Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.

Original language	English (US)
Pages (from-to)	2442-2447
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	61
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2020.1768388
State	Published - Aug 23 2020

Keywords

Hodgkin lymphoma
PET (positron emission tomography)
radiotherapy

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1768388

Cite this

Ha, C. S., LeBlanc, M., Schöder, H., Pinnix, C. C., Bartlett, N. L., Evens, A. M., Hsi, E. D., Rimsza, L., Knopp, M. V., Zhang, J., Leonard, J. P., Kahl, B. S., Li, H., Smith, S., Constine, L. S., & Friedberg, J. W. (2020). Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 61(10), 2442-2447. https://doi.org/10.1080/10428194.2020.1768388

Ha, CS, LeBlanc, M, Schöder, H, Pinnix, CC, Bartlett, NL, Evens, AM, Hsi, ED, Rimsza, L, Knopp, MV, Zhang, J, Leonard, JP, Kahl, BS, Li, H, Smith, S, Constine, LS & Friedberg, JW 2020, 'Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816', Leukemia and Lymphoma, vol. 61, no. 10, pp. 2442-2447. https://doi.org/10.1080/10428194.2020.1768388

@article{df603796c4394d69b77845bfdddba0f6,

title = "Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816",

abstract = "The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2–58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates. Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.",

keywords = "Hodgkin lymphoma, PET (positron emission tomography), radiotherapy",

author = "Ha, {Chul S.} and Michael LeBlanc and Heiko Sch{\"o}der and Pinnix, {Chelsea C.} and Bartlett, {Nancy L.} and Evens, {Andrew M.} and Hsi, {Eric D.} and Lisa Rimsza and Knopp, {Michael V.} and Jun Zhang and Leonard, {John P.} and Kahl, {Brad S.} and Hongli Li and Sonali Smith and Constine, {Louis S.} and Friedberg, {Jonathan W.}",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = aug,

day = "23",

doi = "10.1080/10428194.2020.1768388",

language = "English (US)",

volume = "61",

pages = "2442--2447",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma

T2 - a secondary analysis of SWOG S0816

AU - Ha, Chul S.

AU - LeBlanc, Michael

AU - Schöder, Heiko

AU - Pinnix, Chelsea C.

AU - Bartlett, Nancy L.

AU - Evens, Andrew M.

AU - Hsi, Eric D.

AU - Rimsza, Lisa

AU - Knopp, Michael V.

AU - Zhang, Jun

AU - Leonard, John P.

AU - Kahl, Brad S.

AU - Li, Hongli

AU - Smith, Sonali

AU - Constine, Louis S.

AU - Friedberg, Jonathan W.

PY - 2020/8/23

Y1 - 2020/8/23

N2 - The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2–58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates. Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.

AB - The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2–58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates. Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.

KW - Hodgkin lymphoma

KW - PET (positron emission tomography)

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85086040903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086040903&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1768388

DO - 10.1080/10428194.2020.1768388

M3 - Article

C2 - 32452714

AN - SCOPUS:85086040903

SN - 1042-8194

VL - 61

SP - 2442

EP - 2447

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this